There were 839 press releases posted in the last 24 hours and 442,291 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image